LY-354740 (Eli Lilly).
Lilly is developing LY-354740, the lead compound in a series of derivatives of the metabotropic glutamate receptor group II agonist L-CCG-1, for the potential treatment of anxiety [212536], [276941], [276942].
Pilc
Andrzej
A
Institute of Pharmacology, Polish Academy of Sciences, 31-343 Krakow, Smetna 12, Poland. nfpilc@cyf-kr.edu.pl
D000818:Animals; D014151:Anti-Anxiety Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy; D001643:Bridged Bicyclo Compounds / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D018690:Excitatory Amino Acid Agonists / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors
D014151:Anti-Anxiety Agents; D001643:Bridged Bicyclo Compounds; D018690:Excitatory Amino Acid Agonists; D018094:Receptors, Metabotropic Glutamate; C104753:eglumetad